Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

The interactive effects of ketamine and magnesium upon depressive-like pathology.

Razmjou S, Litteljohn D, Rudyk C, Syed S, Clarke M, Pentz R, Dwyer Z, Hayley S.

Neuropsychiatr Dis Treat. 2016 Sep 8;12:2049-56. doi: 10.2147/NDT.S111131.

2.

Preclinical animal anxiety research - flaws and prejudices.

Ennaceur A, Chazot PL.

Pharmacol Res Perspect. 2016 Mar 8;4(2):e00223. doi: 10.1002/prp2.223. Review.

3.

New Hippocampal Neurons Mature Rapidly in Response to Ketamine But Are Not Required for Its Acute Antidepressant Effects on Neophagia in Rats.

Soumier A, Carter RM, Schoenfeld TJ, Cameron HA.

eNeuro. 2016 Mar 31;3(2). pii: ENEURO.0116-15.2016. doi: 10.1523/ENEURO.0116-15.2016.

4.

Modulation of anxiety and fear via distinct intrahippocampal circuits.

Engin E, Smith KS, Gao Y, Nagy D, Foster RA, Tsvetkov E, Keist R, Crestani F, Fritschy JM, Bolshakov VY, Hajos M, Heldt SA, Rudolph U.

Elife. 2016 Mar 14;5:e14120. doi: 10.7554/eLife.14120.

5.

Previous Ketamine Produces an Enduring Blockade of Neurochemical and Behavioral Effects of Uncontrollable Stress.

Amat J, Dolzani SD, Tilden S, Christianson JP, Kubala KH, Bartholomay K, Sperr K, Ciancio N, Watkins LR, Maier SF.

J Neurosci. 2016 Jan 6;36(1):153-61. doi: 10.1523/JNEUROSCI.3114-15.2016.

6.

The positive effect on ketamine as a priming adjuvant in antidepressant treatment.

Melo A, Kokras N, Dalla C, Ferreira C, Ventura-Silva AP, Sousa N, Pêgo JM.

Transl Psychiatry. 2015 May 26;5:e573. doi: 10.1038/tp.2015.66.

7.

NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism.

Kiselycznyk C, Jury NJ, Halladay LR, Nakazawa K, Mishina M, Sprengel R, Grant SG, Svenningsson P, Holmes A.

Behav Brain Res. 2015;287:89-95. doi: 10.1016/j.bbr.2015.03.023.

8.

Effect of antidepressant drugs on the vmPFC-limbic circuitry.

Chang CH, Chen MC, Lu J.

Neuropharmacology. 2015 May;92:116-24. doi: 10.1016/j.neuropharm.2015.01.010.

9.

Comparison of antidepressant-like and abuse-related effects of phencyclidine in rats.

Hillhouse TM, Porter JH, Negus SS.

Drug Dev Res. 2014 Dec;75(8):479-88. doi: 10.1002/ddr.21228.

10.

Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats.

Hillhouse TM, Porter JH, Negus SS.

Psychopharmacology (Berl). 2014 Jul;231(13):2705-16. doi: 10.1007/s00213-014-3451-3.

11.

Effects of striatal ΔFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice.

Donahue RJ, Muschamp JW, Russo SJ, Nestler EJ, Carlezon WA Jr.

Biol Psychiatry. 2014 Oct 1;76(7):550-8. doi: 10.1016/j.biopsych.2013.12.014.

12.

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants.

Browne CA, Lucki I.

Front Pharmacol. 2013 Dec 27;4:161. doi: 10.3389/fphar.2013.00161. Review.

13.

Depletion of serotonin in the basolateral amygdala elevates glutamate receptors and facilitates fear-potentiated startle.

Tran L, Lasher BK, Young KA, Keele NB.

Transl Psychiatry. 2013 Sep 3;3:e298. doi: 10.1038/tp.2013.66.

14.

Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds.

Neelkantan N, Mikhaylova A, Stewart AM, Arnold R, Gjeloshi V, Kondaveeti D, Poudel MK, Kalueff AV.

ACS Chem Neurosci. 2013 Aug 21;4(8):1137-50. doi: 10.1021/cn400090q. Review.

15.

Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats.

Parise EM, Alcantara LF, Warren BL, Wright KN, Hadad R, Sial OK, Kroeck KG, Iñiguez SD, Bolaños-Guzmán CA.

Biol Psychiatry. 2013 Nov 15;74(10):750-9. doi: 10.1016/j.biopsych.2013.04.027.

16.

A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia.

Yee BK, Singer P.

Cell Tissue Res. 2013 Oct;354(1):221-46. doi: 10.1007/s00441-013-1611-0. Review.

17.

Chronic antidepressant treatment impairs the acquisition of fear extinction.

Burghardt NS, Sigurdsson T, Gorman JM, McEwen BS, LeDoux JE.

Biol Psychiatry. 2013 Jun 1;73(11):1078-86. doi: 10.1016/j.biopsych.2012.10.012.

18.

Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Mathews DC, Henter ID, Zarate CA.

Drugs. 2012 Jul 9;72(10):1313-33. doi: 10.2165/11633130-000000000-00000. Review.

19.

Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology.

Kyzar EJ, Collins C, Gaikwad S, Green J, Roth A, Monnig L, El-Ounsi M, Davis A, Freeman A, Capezio N, Stewart AM, Kalueff AV.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):194-202. doi: 10.1016/j.pnpbp.2012.01.003.

20.

Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants.

Malkesman O, Austin DR, Tragon T, Henter ID, Reed JC, Pellecchia M, Chen G, Manji HK.

Mol Psychiatry. 2012 Jul;17(8):770-80. doi: 10.1038/mp.2011.77.

Supplemental Content

Support Center